Phase 2 study of parsaclisib (INCB050465), a highly...

  • Main
  • 2020 / 11
  • Phase 2 study of parsaclisib (INCB050465), a highly...

Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)

Coleman, Morton, Belada, David, Casasnovas, René-Olivier, Gressin, Rémy, Lee, Hui-Peng, Mehta, Amitkumar, Munoz, Javier, Verhoef, Gregor, Corrado, Claudia, DeMarini, Douglas J., Zhao, Wanying, Li, J
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Leukemia & Lymphoma
DOI:
10.1080/10428194.2020.1832660
Date:
November, 2020
File:
PDF, 1.39 MB
2020
Conversion to is in progress
Conversion to is failed